Lion Biotechnologies Inc. (LBIO) 12.34 $LBIO
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 8:12AM CDT
EYES: 13.35 (-0.35), PBR.A: 8.91 (+0.23), BALT: 1.61 (-0.04), LBIO: 12.34 (-0.08), RGLS: 17.49 (-0.80), ZEP: 19.88 (-0.03), WBAI: 17.20 (+0.16), PBR: 9.99 (+0.59), INO: 10.35 (-0.25), LGF: 32.43 (+0.49), CHL: 75.00 (+0.71), PSTR: 4.58 (-0.05), MPO: 1.09 (-0.07), CBMG: 29.51 (-1.85)
Lion Biotechnologies Announces Publication of Data From Clinical Study of Metastatic Cervical Cancer Patients Treated With HPV-TIL
GlobeNewswire - Wed Apr 08, 7:26AM CDT
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that data from a metastatic cervical cancer study conducted by the National Cancer Institute (NCI) was published in the Journal of Clinical Oncology in an article titled "Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells". Data from the trial showed objective responses, including durable, complete regressions, in patients after a single infusion of HPV-TIL.
LBIO: 12.34 (-0.08)
Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched
at The Street - Tue Apr 07, 7:02AM CDT
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
ADXS: 23.34 (-0.27), MRK: 57.60 (+0.09), INCY: 107.34 (-0.51), CLDX: 30.10 (+0.19), LBIO: 12.34 (-0.08), JUNO: 56.66 (-1.06), BMY: 65.80 (-0.20), TWTR: 50.82 (-0.59), NVS: 104.28 (-1.22), CELG: 118.71 (+2.62)
Lion Biotechnologies Announces Positive Data From a TIL-Ipilimumab Combination Study in Melanoma
GlobeNewswire - Mon Mar 30, 5:00AM CDT
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that researchers from Moffitt Cancer Center reported positive results from a pilot trial of TIL and ipilimumab in patients with metastatic melanoma. The data from the trial, which Lion partially sponsored, were presented at the Society of Surgical Oncology 2015 meeting in Houston, TX on Friday, March 27, 2015.
LBIO: 12.34 (-0.08)
Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31
PR Newswire - Wed Mar 25, 6:30AM CDT
Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Oxis CEO Tony Cataldo will hold a conference call on Tuesday March 31, 2015 at 4:15pm EST to update shareholders and other interested parties on corporate developments at Oxis Biotech, Inc.
LBIO: 12.34 (-0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 11:46AM CDT
RXII: 0.63 (-0.04), RADA: 2.53 (-0.06), AQXP: 7.77 (-0.03), IMGN: 9.96 (-0.29), NRX: 8.26 (-0.08), ASPX: 100.88 (-0.01), LBIO: 12.34 (-0.08), SLTD: 4.54 (+0.14), MEIP: 2.16 (-0.02), RESN: 3.90 (+0.06), SEED: 1.77 (+0.16), AKER: 4.65 (unch), CALA: 13.41 (-0.35), ENVI: 1.77 (-0.04), IKGH: 1.74 (-0.11), WHLR: 2.34 (unch), LEU: 5.22 (+0.58), AMCO: 1.09 (+0.04), CAPN: 6.87 (+0.01), RCON: 1.90 (-0.10)
Engineered TCR and CAR Immunotherapeutics Analysis Report 2015
M2 - Thu Mar 19, 12:08PM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvztx7/engineered_tcr) has announced the addition of the "Engineered TCR and CAR Immunotherapeutics 2015" report to their offering. This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies. However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities. This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. What will you find in the report? - Profiles of TCR and CAR immunotherapeutics in development - Competitor analysis of CD19 CAR T cells - Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value - Target analysis of TCR T cells in R&D - CAR T Cell pipeline in hematology - CAR T Cell pipeline in solid tumors - Allogeneic TCR and CAR T cells in R&D - Universal antibody-targeted CAR T cells and NK cells - Pipeline of most promising TILs, NK cells, DLIs and CTLs - Technologies needed for next generations of TCR and CAR immunotherapeutics - Profiles of biotechnology companies incl. financing and licensing/partnering - Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs - Stakeholder analysis (established, emerging, non-US, technology providing companies) - Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs - Analysis of major partnering deals between Big pharma and technology companies - Economic terms of pharma-biotech deals - Opportunities for biotech-biotech deals in the TCR and CAR field - Potential to raise private money with TCR and CAR technologies - Success in initial public offerings and follow on offerings with TCRs and CARs - Limitations and hurdles with current TCR and CAR immunotherapeutics - Opportunities for novel TCR and CAR immunotherapeutics - Pricing of TCR and CAR immunotherapeutics - Aspects of manufacturing and commercialization Who will benefit from the report? - Venture capital, private equity and investment managers - Financial analysts - CFO - Business development and licensing (BDL) specialists - Marketing managers - CEO, COO and managing directors - Corporate strategy, product and portfolio analysts and managers - Chief Technology Officer - Cell technology and manufacturing specialists - Clinical and preclinical development specialists Key Topics Covered: 1 Introduction 2 Executive Summary 3 Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 4 Pipeline Analysis 5 Technology Companies 6 Pharmaceutical Companies 7 Stakeholder Analysis 8 Selected Technology Profiles 9 Business Perspective on TCR and CAR Immunotherapeutics 10 Outlook for TCR and CAR Immunotherapeutics Companies Mentioned - Adaptimmune - Altor Biosciences - Amgen - Applied Immune Technologies - AstraZeneca - Autolus - Bellicum Pharmaceuticals - Bluebird bio - Cardio3 BioSciences - Celgene - Conkwest - CRISPR Therapeutics - CytomX - Editas Medicine - Eli Lilly - Eureka Therapeutics - GlaxoSmithKline - Immunocore - Intellia Therapeutics - Intrexon - Janssen (J&J) - Juno Therapeutics - Kite Pharma - Lion Biotechnologies - Medigene - Nextera - Novartis - Pfizer - Roche - Servier For more information visit http://www.researchandmarkets.com/research/mv...neered_tcr
BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), AMGN: 167.91 (-1.26), LBIO: 12.34 (-0.08), JUNO: 56.66 (-1.06), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), CELGZ: 2.76 (-0.12)
'Mad Money' Lightning Round: I'm Staying Away From Five Below
at The Street - Thu Mar 19, 5:00AM CDT
Cramer isn't crazy about Dicerna Pharmaceuticals and Ziopharm Oncology but he likes Akamai and Lion Biotechnologies.
ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 42.56 (+0.26), ZIOP: 10.81 (-0.39), HALO: 16.86 (-0.08), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), JUNO: 56.66 (-1.06), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
at The Street - Wed Mar 18, 7:01PM CDT
The Federal Reserve is smarter than you think, Cramer says.
TSLA: 218.43 (-0.17), ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), FB: 81.53 (-0.88), WFC: 54.70 (-0.16), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), PLKI: 59.22 (+2.06), SBUX: 51.84 (+2.41), ESPR: 104.60 (-4.29), RCPT: 169.88 (-1.26), CRZO: 53.43 (-0.60), CRL: 77.40 (-0.49), MMP: 82.31 (+0.61), ROST: 104.38 (-0.13), REGN: 480.09 (+0.01)
Lion Bio closes equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:58AM CST
LBIO: 12.34 (-0.08)
Lion Biotechnologies Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Mar 03, 8:10AM CST
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the closing of its underwritten public offering of 9,200,000 shares of its common stock at $8.00 per share, including 1,200,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $73.6 million, before deducting underwriting discounts and commissions and offering expenses payable by Lion.
LBIO: 12.34 (-0.08)
Lion Biotechnologies to Present at Cowen and Company's 35th Annual Healthcare Conference
GlobeNewswire - Mon Mar 02, 7:35AM CST
Lion Biotechnologies, Inc. (Nasdaq:LBIO) announced that president and CEO Elma Hawkins, PhD, will present at Cowen and Company's 35 Annual Healthcare Conference on Wednesday, March 4, 2015. Dr. Hawkins will present at 8:40 a.m. EST.
LBIO: 12.34 (-0.08)
Lion Biotech prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 10:06AM CST
LBIO: 12.34 (-0.08)
Lion Biotechnologies names Ryan Maynard as director and chair of Audit Committee
M2 - Wed Feb 18, 6:44AM CST
Biotechnology company Lion Biotechnologies (Other OTC:LBIO) said on Tuesday that its board of directors has elected Ryan Maynard as its director and chair of the audit committee with immediate effect.
LBIO: 12.34 (-0.08), RIGL: 4.88 (+0.55)
Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
GlobeNewswire - Tue Feb 17, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Ryan Maynard to serve as a director and chair of the audit committee. His appointment is effective immediately.
LBIO: 12.34 (-0.08), RIGL: 4.88 (+0.55)
Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology
GlobeNewswire - Wed Feb 11, 9:55AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to intellectual property related for a next-generation TIL technology for the treatment of metastatic melanoma. This announcement follows a separate exclusive licensing agreement with the NIH for other TIL technologies, which was announced earlier this week.
LBIO: 12.34 (-0.08)
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma
GlobeNewswire - Tue Feb 10, 8:07AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institute of Health (NIH) to certain patents to develop and commercialize TIL therapy in the treatment of metastatic melanoma.
LBIO: 12.34 (-0.08)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Wed Apr 08, 8:12AM CDT
EYES: 13.35 (-0.35), PBR.A: 8.91 (+0.23), BALT: 1.61 (-0.04), LBIO: 12.34 (-0.08), RGLS: 17.49 (-0.80), ZEP: 19.88 (-0.03), WBAI: 17.20 (+0.16), PBR: 9.99 (+0.59), INO: 10.35 (-0.25), LGF: 32.43 (+0.49), CHL: 75.00 (+0.71), PSTR: 4.58 (-0.05), MPO: 1.09 (-0.07), CBMG: 29.51 (-1.85)
Lion Biotechnologies Announces Publication of Data From Clinical Study of Metastatic Cervical Cancer Patients Treated With HPV-TIL
GlobeNewswire - Wed Apr 08, 7:26AM CDT
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that data from a metastatic cervical cancer study conducted by the National Cancer Institute (NCI) was published in the Journal of Clinical Oncology in an article titled "Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirus-Targeted Tumor-Infiltrating T Cells". Data from the trial showed objective responses, including durable, complete regressions, in patients after a single infusion of HPV-TIL.
LBIO: 12.34 (-0.08)
Stock Index Tracking Red-Hot Cancer Immunotherapy Field Launched
at The Street - Tue Apr 07, 7:02AM CDT
The Loncar Cancer Immunotherapy Index (LCINDX) tracks biopharma companies developing (or already marketing) drugs which use the body's own immune system to target and kill cancer cells.
ADXS: 23.34 (-0.27), MRK: 57.60 (+0.09), INCY: 107.34 (-0.51), CLDX: 30.10 (+0.19), LBIO: 12.34 (-0.08), JUNO: 56.66 (-1.06), BMY: 65.80 (-0.20), TWTR: 50.82 (-0.59), NVS: 104.28 (-1.22), CELG: 118.71 (+2.62)
Lion Biotechnologies Announces Positive Data From a TIL-Ipilimumab Combination Study in Melanoma
GlobeNewswire - Mon Mar 30, 5:00AM CDT
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced that researchers from Moffitt Cancer Center reported positive results from a pilot trial of TIL and ipilimumab in patients with metastatic melanoma. The data from the trial, which Lion partially sponsored, were presented at the Society of Surgical Oncology 2015 meeting in Houston, TX on Friday, March 27, 2015.
LBIO: 12.34 (-0.08)
Oxis Biotech Inc. Announces Corporate Update Conference Call for March 31
PR Newswire - Wed Mar 25, 6:30AM CDT
Oxis International, Inc. (OXIS) (OXI.PA) a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Oxis CEO Tony Cataldo will hold a conference call on Tuesday March 31, 2015 at 4:15pm EST to update shareholders and other interested parties on corporate developments at Oxis Biotech, Inc.
LBIO: 12.34 (-0.08)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Mar 23, 11:46AM CDT
RXII: 0.63 (-0.04), RADA: 2.53 (-0.06), AQXP: 7.77 (-0.03), IMGN: 9.96 (-0.29), NRX: 8.26 (-0.08), ASPX: 100.88 (-0.01), LBIO: 12.34 (-0.08), SLTD: 4.54 (+0.14), MEIP: 2.16 (-0.02), RESN: 3.90 (+0.06), SEED: 1.77 (+0.16), AKER: 4.65 (unch), CALA: 13.41 (-0.35), ENVI: 1.77 (-0.04), IKGH: 1.74 (-0.11), WHLR: 2.34 (unch), LEU: 5.22 (+0.58), AMCO: 1.09 (+0.04), CAPN: 6.87 (+0.01), RCON: 1.90 (-0.10)
Engineered TCR and CAR Immunotherapeutics Analysis Report 2015
M2 - Thu Mar 19, 12:08PM CDT
Research and Markets (http://www.researchandmarkets.com/research/mvztx7/engineered_tcr) has announced the addition of the "Engineered TCR and CAR Immunotherapeutics 2015" report to their offering. This report Engineered TCR and CAR Immunotherapeutics 2015: A comparative analysis of the landscape of and business opportunities with TCR and CAR antibodies, T cells, NK cells, TILs, DLIs & DLIs as of March 2015 brings you up-to-date regarding key players, key technologies, TCR and CAR immunotherapeutic projects, business deals and private and public financing rounds. The report analyzes the TCR and CAR immunotherapeutic pipelines and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of TCR and CAR immunotherapeutics in terms of partnering economic conditions, private financing rounds and (initial) public offerings with the resulting market capitalization of companies. However, progress in clinical trials and supply of clinical grade batches reveals some major limitations which need to be surmounted and the problems solved if TCR and CAR immunotherapeutics want to become commercially viable and successful products. This report describes the challenges and limitations and identifies solutions provided by new technologies which offer tremendous business opportunities. This report has been built in a bottom-up basis by desktop search to identify and describe company, product, technology and business/financing profiles which then are evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. What will you find in the report? - Profiles of TCR and CAR immunotherapeutics in development - Competitor analysis of CD19 CAR T cells - Options to improve CAR T cells regarding efficacy, safety, manufacturing and commercial value - Target analysis of TCR T cells in R&D - CAR T Cell pipeline in hematology - CAR T Cell pipeline in solid tumors - Allogeneic TCR and CAR T cells in R&D - Universal antibody-targeted CAR T cells and NK cells - Pipeline of most promising TILs, NK cells, DLIs and CTLs - Technologies needed for next generations of TCR and CAR immunotherapeutics - Profiles of biotechnology companies incl. financing and licensing/partnering - Profiles and scope of interest of Big Pharma/Biotech companies for TCRs & CARs - Stakeholder analysis (established, emerging, non-US, technology providing companies) - Potential of alternative adoptive immunotherapies with NK cells, TILs, CTLs and DLIs - Analysis of major partnering deals between Big pharma and technology companies - Economic terms of pharma-biotech deals - Opportunities for biotech-biotech deals in the TCR and CAR field - Potential to raise private money with TCR and CAR technologies - Success in initial public offerings and follow on offerings with TCRs and CARs - Limitations and hurdles with current TCR and CAR immunotherapeutics - Opportunities for novel TCR and CAR immunotherapeutics - Pricing of TCR and CAR immunotherapeutics - Aspects of manufacturing and commercialization Who will benefit from the report? - Venture capital, private equity and investment managers - Financial analysts - CFO - Business development and licensing (BDL) specialists - Marketing managers - CEO, COO and managing directors - Corporate strategy, product and portfolio analysts and managers - Chief Technology Officer - Cell technology and manufacturing specialists - Clinical and preclinical development specialists Key Topics Covered: 1 Introduction 2 Executive Summary 3 Profiles of TCR & CAR Immunotherapeutics, NK Cells, TILs, DLIs and CTLs 4 Pipeline Analysis 5 Technology Companies 6 Pharmaceutical Companies 7 Stakeholder Analysis 8 Selected Technology Profiles 9 Business Perspective on TCR and CAR Immunotherapeutics 10 Outlook for TCR and CAR Immunotherapeutics Companies Mentioned - Adaptimmune - Altor Biosciences - Amgen - Applied Immune Technologies - AstraZeneca - Autolus - Bellicum Pharmaceuticals - Bluebird bio - Cardio3 BioSciences - Celgene - Conkwest - CRISPR Therapeutics - CytomX - Editas Medicine - Eli Lilly - Eureka Therapeutics - GlaxoSmithKline - Immunocore - Intellia Therapeutics - Intrexon - Janssen (J&J) - Juno Therapeutics - Kite Pharma - Lion Biotechnologies - Medigene - Nextera - Novartis - Pfizer - Roche - Servier For more information visit http://www.researchandmarkets.com/research/mv...neered_tcr
BLCM: 27.88 (-0.46), KITE: 60.58 (-0.35), AMGN: 167.91 (-1.26), LBIO: 12.34 (-0.08), JUNO: 56.66 (-1.06), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22), CELGZ: 2.76 (-0.12)
'Mad Money' Lightning Round: I'm Staying Away From Five Below
at The Street - Thu Mar 19, 5:00AM CDT
Cramer isn't crazy about Dicerna Pharmaceuticals and Ziopharm Oncology but he likes Akamai and Lion Biotechnologies.
ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Akamai Technologies Is A Terrific Connectivity Play - Cramer's Lightning Round (3/18/15)
SA Editor Mohit Manghnani - Seeking Alpha - Thu Mar 19, 4:35AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, March 18. Bullish Calls: Akamai Technologies (NASDAQ: AKAM ): "This is a content delivery system, and I think it's terrific. We keep...
AR: 42.56 (+0.26), ZIOP: 10.81 (-0.39), HALO: 16.86 (-0.08), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), JUNO: 56.66 (-1.06), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), ROST: 104.38 (-0.13)
Jim Cramer's 'Mad Money' Recap: The Fed Does the Right Thing
at The Street - Wed Mar 18, 7:01PM CDT
The Federal Reserve is smarter than you think, Cramer says.
TSLA: 218.43 (-0.17), ZIOP: 10.81 (-0.39), AR: 42.56 (+0.26), DRNA: 24.18 (-0.25), AKAM: 75.74 (-0.53), FB: 81.53 (-0.88), WFC: 54.70 (-0.16), LBIO: 12.34 (-0.08), FIVE: 36.04 (+0.10), PLKI: 59.22 (+2.06), SBUX: 51.84 (+2.41), ESPR: 104.60 (-4.29), RCPT: 169.88 (-1.26), CRZO: 53.43 (-0.60), CRL: 77.40 (-0.49), MMP: 82.31 (+0.61), ROST: 104.38 (-0.13), REGN: 480.09 (+0.01)
Lion Bio closes equity offering
Seeking Alpha - at Seeking Alpha - Tue Mar 03, 8:58AM CST
LBIO: 12.34 (-0.08)
Lion Biotechnologies Announces Closing of Underwritten Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
GlobeNewswire - Tue Mar 03, 8:10AM CST
Lion Biotechnologies, Inc. (Nasdaq:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor infiltrating lymphocytes (TIL), today announced the closing of its underwritten public offering of 9,200,000 shares of its common stock at $8.00 per share, including 1,200,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares, resulting in gross proceeds from the offering of $73.6 million, before deducting underwriting discounts and commissions and offering expenses payable by Lion.
LBIO: 12.34 (-0.08)
Lion Biotechnologies to Present at Cowen and Company's 35th Annual Healthcare Conference
GlobeNewswire - Mon Mar 02, 7:35AM CST
Lion Biotechnologies, Inc. (Nasdaq:LBIO) announced that president and CEO Elma Hawkins, PhD, will present at Cowen and Company's 35 Annual Healthcare Conference on Wednesday, March 4, 2015. Dr. Hawkins will present at 8:40 a.m. EST.
LBIO: 12.34 (-0.08)
Lion Biotech prices equity offering
Seeking Alpha - at Seeking Alpha - Thu Feb 26, 10:06AM CST
LBIO: 12.34 (-0.08)
Lion Biotechnologies names Ryan Maynard as director and chair of Audit Committee
M2 - Wed Feb 18, 6:44AM CST
Biotechnology company Lion Biotechnologies (Other OTC:LBIO) said on Tuesday that its board of directors has elected Ryan Maynard as its director and chair of the audit committee with immediate effect.
LBIO: 12.34 (-0.08), RIGL: 4.88 (+0.55)
Lion Biotechnologies Appoints Ryan Maynard Director and Chair of Audit Committee
GlobeNewswire - Tue Feb 17, 7:01AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that its board of directors has appointed Ryan Maynard to serve as a director and chair of the audit committee. His appointment is effective immediately.
LBIO: 12.34 (-0.08), RIGL: 4.88 (+0.55)
Lion Biotechnologies Obtains Exclusive License From NIH for Next-Generation TIL Technology
GlobeNewswire - Wed Feb 11, 9:55AM CST
Lion Biotechnologies, Inc. (OTCQB:LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to intellectual property related for a next-generation TIL technology for the treatment of metastatic melanoma. This announcement follows a separate exclusive licensing agreement with the NIH for other TIL technologies, which was announced earlier this week.
LBIO: 12.34 (-0.08)
Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL Therapy in Metastatic Melanoma
GlobeNewswire - Tue Feb 10, 8:07AM CST
Lion Biotechnologies, Inc. (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institute of Health (NIH) to certain patents to develop and commercialize TIL therapy in the treatment of metastatic melanoma.
LBIO: 12.34 (-0.08)
